Chronic Hand Dermatitis
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Topical Ruxolitinib in Chronic Hand Dermatitis
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
Apremilast and Moderate to Severe Chronic Hand Dermatitis
Chronic Hand Eczema - Self-management and Prognosis
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis
Comparison Study With E-DO in Chronic Hand Dermatitis
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis